AbbVie Reports Q3 2026 Revenue of $17.4 Billion, Up 10.3%
AbbVie said Q3 2026 revenue rose 10.3% year over year to $17.4 billion, in line with estimates. Non-GAAP profit was $3.82 per share, 1.3% above analysts’ consensus.
Story updates
01:32:20 PM UTC
SquawkNews
AbbVie announced its third-quarter 2026 financial results, reporting net revenues of $17.404 billion and an adjusted diluted EPS of $3.82, both of which surpassed analyst consensus estimates. Driven by strong performance in its immunology and neuroscience portfolios, the company raised its full-year 2026 adjusted diluted EPS guidance to a range of $13.95 to $13.99. Additionally, the board of directors declared a 5.2% increase in the quarterly cash dividend, raising it from $1.73 to $1.82 per share, payable on February 16, 2027. Management highlighted the company's solid execution and long-term growth potential, supported by recent regulatory approvals and clinical data.
Pharmaceutical company AbbVie NYSE:ABBV met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non-GAAP profit of $3.82 per share was 1.3% above analysts’ consensus estimates.For more on AbbVie, read the full research report, available free.A…